Evidence map›Paper›PMID 26573286›Full record

ArticleHuman cell2016

Eribulin upregulates miR-195 expression and downregulates Wnt3a expression in non-basal-like type of triple-negative breast cancer cell MDA-MB-231.

Kanji Furuya, Akiko Sasaki, Yuko Tsunoda, Mayumi Tsuji, Yuko Udaka, Hideto Oyamada, Hiromichi Tsuchiya, Katsuji Oguchi

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. MicroRNA-195: a review of its role in cancers.OncoTargets and therapy · 2018
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kanji FuruyaDepartment of Pharmacology, Showa University School of Medicine, Hatanodai 1-5-8, Shinagawaku, Tokyo, 142-8555, Japan. k.ayuruf.5@gmail.com.
Akiko SasakiDepartment of Pharmacology, Showa University School of Medicine, Hatanodai 1-5-8, Shinagawaku, Tokyo, 142-8555, Japan.
Yuko TsunodaKameda Medical Center, Breast Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
Mayumi TsujiDepartment of Pharmacology, Showa University School of Medicine, Hatanodai 1-5-8, Shinagawaku, Tokyo, 142-8555, Japan.
Yuko UdakaDepartment of Pharmacology, Showa University School of Medicine, Hatanodai 1-5-8, Shinagawaku, Tokyo, 142-8555, Japan.
Hideto OyamadaDepartment of Pharmacology, Showa University School of Medicine, Hatanodai 1-5-8, Shinagawaku, Tokyo, 142-8555, Japan.
Hiromichi TsuchiyaDepartment of Pharmacology, Showa University School of Medicine, Hatanodai 1-5-8, Shinagawaku, Tokyo, 142-8555, Japan.
Katsuji OguchiDepartment of Pharmacology, Showa University School of Medicine, Hatanodai 1-5-8, Shinagawaku, Tokyo, 142-8555, Japan.
Showa University · JPKameda Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC), which does not show hormone sensitivity, is a poor prognosis disease without an established targeted treatment, so that establishing a therapeutic target for each subtype is desired. In addition, microRNA (miRNA), a non-cording RNA 19-25 nucleotide-longs in length, is known to be involved in regulating gene expression. We examined miRNA expression after exposure to eribulin, MDA-MB-231 cells, non-basal-like type of TNBC cell lines, and HCC1143 cells, basal-like type of TNBC cell lines. The activity of caspase-3 significantly increased compared to the control in MDA-MB-231, whereas no significant difference was observed in HCC1143. The expression level of 20-miRNAs significantly increased compared to the control in MDA-MB-231 after exposure to eribulin. The expression level of 6-miRNAs also significantly increased compared to the control in HCC1143. In these 2 cell types, miR-125b-1 and miR-195 were commonly expressed. While the expression level of miR-125b-1 decreased in both cells, the expression level of miR-195 increased in MDA-MB-231 and decreased in HCC1143. The expression level of miR-195 targeting Wnt3a significantly decreased compared to the control in MDA-MB-231, whereas it significantly increased in HCC1143. These results showed that exposure to eribulin highly increased the expression of miR-195 while it decreased the expression of Wnt3a in non-basal-like type of TNBC. Some miRNAs are known to regulate other signaling pathways involved in human pathogenesis by regulating the Wnt signaling pathway, and miRNA can act as a tumor-suppressing gene; therefore, miR-195 may serve as a therapeutic target in non-basal-like type of TNBC.

Indexed as

Genes, Tumor SuppressorBreast NeoplasmsCell Line, TumorDown-RegulationFemaleFuransGene ExpressionHumansKetonesMicroRNAsMolecular Targeted TherapyPolyether PolyketidesSignal TransductionUp-RegulationWnt3A ProteineribulinFuransKetonesMicroRNAsMIRN195 microRNA, humanPolyether PolyketidesWnt3A ProteinWNT3A protein, humanBreast cancerEribulinMicroRNATriple negativeWnt3a

Identifiers

PMID26573286
OpenAlexW2180844450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.